These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38185529)

  • 1. [Pathophysiology, diagnosis, and therapy for the management of acquired clotting factor deficiency].
    Yu DD; Liu W; Zhang L
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):956-962. PubMed ID: 38185529
    [No Abstract]   [Full Text] [Related]  

  • 2. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance for plasma-derived clotting factor concentrates.
    Tagariello G; Cavallin F; Davoli PG; Gajo GB; De Biasi E; Traldi A
    Lancet; 1993 Dec; 342(8885):1489. PubMed ID: 7902506
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: what is known?].
    Heindl B; Spannagl M
    Anaesthesist; 2006 Sep; 55(9):926, 928-36. PubMed ID: 16721605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rational substitution therapy in blood coagulation disorders].
    Lechner K
    Infusionsther Klin Ernahr; 1980 Aug; 7(4):190-4. PubMed ID: 7191414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne).
    O'Leary DS; Ruymann FB; Conrad ME
    J Lab Clin Med; 1971 Jan; 77(1):23-32. PubMed ID: 5540427
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study Group.
    Hassett J; Gjerset GF; Mosley JW; Fletcher MA; Donegan E; Parker JW; Counts RB; Aledort LM; Lee H; Pike MC
    Blood; 1993 Aug; 82(4):1351-7. PubMed ID: 8353293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing clotting factor replacement therapy in hemophilia: a global need.
    Srivastava A
    Hematology; 2005; 10 Suppl 1():229-30. PubMed ID: 16188679
    [No Abstract]   [Full Text] [Related]  

  • 9. Clotting factor concentrates.
    Br Med J; 1972 Jan; 1(5792):66-7. PubMed ID: 5007069
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clotting factor concentrates].
    Barthels M; Schramm W
    Hamostaseologie; 2004 Nov; 24(4):286-97. PubMed ID: 15526073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future of coagulation factor replacement therapy.
    Peyvandi F; Garagiola I; Seregni S
    J Thromb Haemost; 2013 Jun; 11 Suppl 1():84-98. PubMed ID: 23809113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant blood clotting proteins for hemophilia therapy.
    Limentani SA; Roth DA; Furie BC; Furie B
    Semin Thromb Hemost; 1993; 19(1):62-72. PubMed ID: 8456325
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee.
    Kasper CK; Lusher JM
    Transfusion; 1993 May; 33(5):422-34. PubMed ID: 8488548
    [No Abstract]   [Full Text] [Related]  

  • 14. Rational perioperative use of clotting factor concentrates and fresh frozen plasma (FFP).
    Muntean W
    Acta Anaesthesiol Scand Suppl; 1997; 111():263-4. PubMed ID: 9421038
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of inhibitors on the use of clotting factor concentrates].
    Barthels M
    Dtsch Med Wochenschr; 2000 Jan; 125(1-2):17-20. PubMed ID: 10650820
    [No Abstract]   [Full Text] [Related]  

  • 16. Replacement therapy with virus-inactivated clotting factor concentrates in patients with severe hemophilia in Heidelberg.
    Zimmermann R; Uhle C; Huth-Kühne A
    Semin Thromb Hemost; 2002 Apr; 28 Suppl 1():75-8. PubMed ID: 12016582
    [No Abstract]   [Full Text] [Related]  

  • 17. Heparinised clotting factor concentrates in patients with Christmas disease and liver disease.
    Preston FE; Malia RG; Lilleyman JS; Blackburn EK
    Thromb Haemost; 1977 Aug; 38(2):504-9. PubMed ID: 579492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time for changing coagulation management in trauma-related massive bleeding.
    Fries D; Innerhofer P; Schobersberger W
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):267-74. PubMed ID: 19390253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular approaches for improved clotting factors for hemophilia.
    Kaufman RJ; Powell JS
    Hematology Am Soc Hematol Educ Program; 2013; 2013():30-6. PubMed ID: 24319159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clotting factor concentrates].
    Barthels M; Oldenburg J
    Hamostaseologie; 2008 Dec; 28(5):387-99. PubMed ID: 19132169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.